The short version of prohibited substance fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 0.9 kDa | Depends on exact fragment sequence and counterion |
| Amino acid sequence | LKKTETQ (commonly cited) | Short actin-binding motif from thymosin beta-4 |
| Common salt form | Acetate salt | Trifluoroacetate also reported in research material |
| Reconstitution solvent | Sterile water or buffer | Gentle mixing; avoid vigorous agitation |
| Solution storage | -20 °C or lower | Aliquot to avoid repeated freeze-thaw cycles |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
== Other == Jane Allen Campbell (1865–1938), American heiress and Italian princess of San Faustino Paul Cushing Child (1902–1994), husband of chef Julia Child, who introduced his wife to fine cuisine, which began her legendary career Victor E. Engstrom (1914–2000), philatelist Vladimir Guryev and Lydia Guryev, a.k.a. Richard and Cynthia Murphy, arrested in their Montclair home June 2010 by FBI; admitted in court to being agents of the Russian Federation and pleaded guilty to conspiracy to act as unregistered agents; expelled with eight others in a prisoner exchange with Russia Florence Merriam Johnson (c. 1876–1954), American Red Cross nurse during World War I, received Florence Nightingale Medal Isaac Newton Lewis (1858–1931), soldier and inventor who created the Lewis gun Mizkif (born 1995), Twitch streamer Pearl Grigsby Richardson (1896–1983), educator and clubwoman
=== Prophecy === In Tales of the Green Lantern Corps Annual #2 (1986), a prophecy narrated to Abin Sur suggests that Mogo will be the last Green Lantern. In a battle with the "Empire of Tears", Ranx the Sentient City will explode a bomb in Mogo's core, killing him and ending the Green Lantern Corps. The Sinestro Corps attack Mogo with Ranx, who started to drill into the planet, with the intention of planting the blink bomb. It was revealed that Mogo is the one who guides the rings of deceased Lanterns to find new replacements and that if he should die, the Corps would be unable to recruit members in this manner. Thanks to the efforts of Sodam Yat, as well as a change in the Book of Oa permitting the Lanterns to use lethal force against the Sinestro Corps, Ranx is destroyed and the Sinestro Corps are driven from Mogo.
=== Euthanasia === Approved procedures for euthanasia of laboratory mice include compressed CO2 gas, injectable barbiturate anesthetics, inhalable anesthetics, such as Halothane, and physical methods, such as cervical dislocation and decapitation. In 2013, the American Veterinary Medical Association issued new guidelines for CO2 induction, stating that a flow rate of 10% to 30% volume/min is optimal for euthanasing laboratory mice.
Plaques on house exteriors inform pedestrians where a well-known personality once lived. Often, these plaques are dedicated to Soviet celebrities little known outside Russia (and similarly, for decorated generals and revolutionaries, little known inside Russia). In addition, Moscow contains many "museum houses" dedicated to famous Russian writers, composers, and artists. Moscow's skyline is rapidly modernizing, with several new towers being constructed. In recent years, the city administration has been widely criticized for the widespread destruction of many historical buildings. As much as a third of historic Moscow has been destroyed during the past few years to make space for luxury apartments and hotels. Other historical buildings—including landmarks such as the 1930 Moskva hotel and the 1913 department store Voyentorg—have been razed and rebuilt, with an inevitable loss in historical value. Critics blame the government for not enforcing conservation laws: during the last 12 years, more than 50 buildings with monument status were torn down, several of these dating back to the 17th century. In addition, some critics wonder if the funds used for reconstructing razed buildings could not be used to renovate decaying structures—such as many works of architect Konstantin Melnikov, as well as the Mayakovskaya metro station. Some organizations, such as the Moscow Architecture Preservation Society and Save Europe's Heritage, are trying to attract international public attention to these problems.
== Ureas == Urea (O=C(NH2)2) is more basic at oxygen than simple amides owing to the combined pi-donation from the two amino groups. One consequence is that the inventory of urea complexes is large, including many homoleptic derivatives. Urea forms a broader range of complexes, reflected by the existence of [M(urea)6](ClO4)3 (M = Ti, Mn). As for other complexes of carboxamide ligands, the MOC(NH2)2 core of urea is planar with a bent M-O-C angle. Biuret (H2NC(O)N(H)C(O)NH2) is a derivative of urea but with two amido groups. Biuret forms a variety of metal complexes, e.g. [Cu(H2NC(O)NHC(O)NH2)2]2+. In addition to the parent urea and biuret, many derivatives are known where N-H is replaced by alkyl or aryl.
Sources: en.wikipedia.org
Recessive mutations often lead to a complete absence of Collagen VI in the extracellular matrix, while there are different types of dominant mutations that can cause partial function of Collagen VI. Mutations in the same three genes can also cause milder phenotypes, namely intermediate collagen VI-related dystrophy and Bethlem myopathy (also called Bethlem muscular dystrophy). Together with Ullrich CMD, these form a continuum of overlapping phenotypes known as collagen VI-related dystrophies. Another form of CMD is rigid spine congenital muscular dystrophy (RSMD1), or rigid spine syndrome, which is caused by mutations in the SELENON gene encoding for selenoprotein N. The exact function of selenoprotein N is unknown, but it is expressed in the rough endoplasmic reticulum of skeletal muscle, heart, brain, lung, and placenta tissues, as well as at high levels in the diaphragm. RSMD1 is characterized by axial and respiratory weakness, spinal rigidity and scoliosis, and muscular atrophy, and while it is a rare form of CMD, SEPN1 mutations are observed in other congenital myopathies. Some of the most common forms of CMDs are dystroglycanopathies caused by glycosylation defects of α-dystroglycan (α-DG), which helps link the extracellular matrix and the cytoskeleton. Dystroglycanopathies are caused by mutations in genes encoding for proteins involved in modifying α-DG after translation of the protein, not mutations in the protein itself.
== Enforcement and compliance costs, and associated privacy concerns == The financial services industry has become more vocal about the rising costs of anti–money laundering regulation and the limited benefits that they claim it brings. One commentator wrote that "[w]ithout facts, [anti–money laundering] legislation has been driven on rhetoric, driving by ill-guided activism responding to the need to be "seen to be doing something" rather than by an objective understanding of its effects on predicate crime. The social panic approach is justified by the language used—we talk of the battle against terrorism or the war on drugs". The Economist magazine has become increasingly vocal in its criticism of such regulation, particularly with reference to countering terrorist financing, referring to it as a "costly failure", although it concedes that other efforts (like reducing identity and credit card fraud) may still be effective at combating money laundering. Money laundering poses significant harms for societies and economies. Data from the United Nations Office on Drugs and Crime (UNODC) estimates that criminal proceeds amounting to 2-5% of the global GDP are being laundered per year. Money laundering facilitates a wide range of underlying crimes. In the European Union there are 22 categories of such crimes, including: arms trafficking; bribery; corruption; cybercrime; drug trafficking; environmental crime; extortion; counterfeiting; financing of terrorism; forgery; fraud; human trafficking; insider trading; racketeering; sexual exploitation; tax evasion; and theft.
ISBN 978-0-87220-923-7. Powell, Anton (1990). Euripides, Women and Sexuality. Routledge Press. ISBN 0-415-01025-X. Pucci, Pietro. "Survival in the Holy Garden." The Violence of Pity In Euripides’ “Medea,” vol. 41, Cornell University Press, 1980, pp. 91–130. JSTOR, http://www.jstor.org/stable/10.7591/j.cttq44w0.6. Accessed 27 Mar. 2023. Rabinowitz, Nancy S. (1993). Anxiety Veiled: Euripides and the Traffic in Women. Cornell University Press. ISBN 0-8014-8091-4. Saïd, Suzanne (2002). "Greeks and Barbarians in Euripides' Tragedies: The End of Differences?". In Harrison, Thomas (ed.). Greeks and Barbarians. Translated by Antonia Nevill. Taylor & Francis. ISBN 0-415-93959-3. Sommerstein, Alan (2002). Greek Drama and Dramatists. Routledge Press. ISBN 0-203-42498-0. ISBN 978-0-203-42498-8 Tessitore, Aristide. "Euripides’ ‘Medea’ and the Problem of Spiritedness." The Review of Politics, vol. 53, no. 4, 1991, pp. 587–601. JSTOR, JSTOR 1407307. Accessed 27 Apr. 2023. Tigani, Francesco (2010), Rappresentare Medea. Dal mito al nichilismo, Aracne. ISBN 978-88-548-3256-5 Mossman, Judith (2011). Medea: Introduction, Translation and Commentary. Warminster: Aris & Phillips. ISBN 978-0-856-68788-4.
Energy column The column labeled "energy" denotes the energy equivalent of (the mass of a neutron minus the mass per nucleon), that is of the mass defect with respect to the neutron, in MeV. Use of the neutron as reference guarantees all nuclides will have a positive value. Mathematically: mn − mnuclide / A. Note that this means that a higher "energy" value actually means that the nuclide has a lower energy. Inversely the mass is A (mn − E / k) where E is the energy, mn is 1.0086649159 and k = 931.4941037 MeV (energy equivalent of the dalton). Omitted if there is no experimental mass determination within 0.0001.
DHRs can also be determined for specific sites in a drug by 2H NMR, and has been used to distinguish between different synthetic methods for ibuprofen and naproxen in one study, and prozac and fluoxetine in another. These studies show that bulk DHR information for EA-IRMS, and site-specific DHRs from 2H NMR have great utility for pharmaceutical drug authenticity testing.
Sources: en.wikipedia.org
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.
Reversed-phase liquid chromatography separates components and reports purity from peak area. Mass spectrometry confirms the molecular mass expected for the sequence. Additional approaches such as peptide mapping or amino acid analysis provide independent confirmation.
Reported percentages depend on the analytical method, the detection wavelength, and whether salts and water are counted. A value above ninety-five percent by chromatography does not by itself establish a correct sequence. Different suppliers also calculate purity against different reference standards.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.